CAMBRIDGE, Mass., Oct. 26, 2011 /PRNewswire/ -- Idenix
Pharmaceuticals, Inc. (NASDAQ: IDIX) announced today that it will
report its financial results for the third quarter of 2011 on
Wednesday, November 2, 2011 after
U.S. financial markets close.
Idenix management will host a conference call at 4:30 p.m. ET on Wednesday,
November 2, 2011 to discuss the company's financial results
for the third quarter of 2011 and provide an update on the
company's development programs.
To access the call please dial (877) 640-9809 U.S./Canada or (914) 495-8528 International and
enter passcode 22292830. There will also be a slide presentation
available to accompany the conference call, which can be accessed
on our website in the Idenix Investor Center at www.idenix.com.
To listen to a live webcast of the call, go to "Calendar of
Events" in the Idenix Investor Center at www.idenix.com. Please log
in approximately 10 minutes before the call to ensure a timely
connection. A replay of the conference call and webcast will be
available until November 16, 2011. To
access the replay, please dial (855)
859-2056 U.S./Canada or (404)
537-3406 International and enter the passcode 22292830.
American Association for the Study of Liver Diseases Meeting
(AASLD)
Idenix will present two posters at AASLD in San Francisco, California:
- McCarville, et al, "Patterns of NS5B mutations in a
3-day clinical trial of HCV non-nucleoside polymerase inhibitor
IDX375" will be presented in a poster session on November 5, 2011 starting at 2:00pm PT
- McCarville, et al, "In vivo resistance profile of IDX320
after 3 days of dosing in genotype 1 HCV-infected patients"
will be presented in a poster session on November 5, 2011 starting at 2:00pm PT
About Idenix
Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a
biopharmaceutical company engaged in the discovery and development
of drugs for the treatment of human viral diseases. Idenix's
current focus is on the treatment of patients with chronic
hepatitis C infection. For further information about Idenix, please
refer to http://www.idenix.com.
Idenix Pharmaceuticals Contacts:
Kelly Barry (617) 995-9033
(media)
Eric Hoffman (617) 224-4485
(investors)
SOURCE Idenix Pharmaceuticals, Inc.